HighVista Strategies LLC Has $2.22 Million Holdings in Scholar Rock Holding Corporation $SRRK

HighVista Strategies LLC raised its holdings in Scholar Rock Holding Corporation (NASDAQ:SRRK) by 90.8% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 59,573 shares of the company’s stock after purchasing an additional 28,343 shares during the quarter. HighVista Strategies LLC’s holdings in Scholar Rock were worth $2,218,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Scholar Rock by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 4,914,927 shares of the company’s stock worth $183,032,000 after acquiring an additional 53,333 shares during the last quarter. Wellington Management Group LLP boosted its position in Scholar Rock by 124.5% during the third quarter. Wellington Management Group LLP now owns 4,545,887 shares of the company’s stock worth $169,289,000 after purchasing an additional 2,521,022 shares during the period. Bellevue Group AG boosted its position in Scholar Rock by 10.1% during the third quarter. Bellevue Group AG now owns 3,244,537 shares of the company’s stock worth $120,827,000 after purchasing an additional 297,242 shares during the period. Eventide Asset Management LLC increased its holdings in shares of Scholar Rock by 9.5% in the second quarter. Eventide Asset Management LLC now owns 2,913,246 shares of the company’s stock valued at $103,192,000 after purchasing an additional 251,638 shares during the last quarter. Finally, Holocene Advisors LP bought a new position in shares of Scholar Rock in the third quarter valued at about $91,670,000. 91.08% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently commented on SRRK shares. Wolfe Research began coverage on shares of Scholar Rock in a report on Tuesday, November 18th. They set an “outperform” rating and a $42.00 target price for the company. Piper Sandler increased their target price on Scholar Rock from $51.00 to $58.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Scholar Rock in a report on Thursday, January 22nd. JPMorgan Chase & Co. upped their price objective on Scholar Rock from $46.00 to $47.00 and gave the company an “overweight” rating in a report on Tuesday, November 18th. Finally, Raymond James Financial reissued a “strong-buy” rating on shares of Scholar Rock in a research report on Tuesday, March 3rd. Four investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Scholar Rock presently has a consensus rating of “Buy” and an average price target of $54.14.

Insider Activity

In related news, insider Caryn Parlavecchio sold 9,035 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total transaction of $420,398.55. Following the sale, the insider owned 169,087 shares in the company, valued at approximately $7,867,618.11. This trade represents a 5.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Jing L. Marantz sold 4,157 shares of Scholar Rock stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total transaction of $193,425.21. Following the completion of the transaction, the insider directly owned 126,012 shares in the company, valued at $5,863,338.36. This trade represents a 3.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 208,470 shares of company stock valued at $9,201,778. Corporate insiders own 13.30% of the company’s stock.

Scholar Rock Price Performance

Shares of NASDAQ SRRK opened at $40.01 on Monday. The stock has a market capitalization of $4.60 billion, a PE ratio of -11.66 and a beta of 0.70. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.95 and a quick ratio of 6.95. The business has a fifty day moving average price of $45.21 and a two-hundred day moving average price of $39.68. Scholar Rock Holding Corporation has a fifty-two week low of $22.71 and a fifty-two week high of $49.82.

Scholar Rock (NASDAQ:SRRK) last released its earnings results on Tuesday, March 3rd. The company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.10. During the same period last year, the business earned ($0.64) EPS. As a group, equities analysts predict that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current fiscal year.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).